Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-04-23
2000-07-11
Crane, L. Eric
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530350, A61K 3816
Patent
active
060873280
ABSTRACT:
A method for preparing a conjugate, and preferably a protein-polysaccharide conjugate, includes functionalizing a first moiety (e.g., a polysaccharide) with one or more pendant haloacyl groups. Thereafter, the functionalized first moiety is reacted with a second moiety, preferably an unmodified protein or a protein to which no thiol groups have been added, to form a covalently linked conjugate. Various different haloacyl reagents can be used in the invention. For example, the haloacyl reagent can be an active ester, an anhydride, a haloacyl chloride, or a haloacyl acid. Specific haloacyl reagents that can be used in the process of the invention include N-succinimidyl-2,3-dibromopropionate and N-succinimidyl iodoacetate. The invention further relates to the conjugates produced by the method of the invention. These conjugates can be used as immunogens or vaccines. Furthermnore, the invention also relates to a method of inducing an immune response in a subject by administering a vaccine made by the method according to the invention.
REFERENCES:
patent: 3278392 (1966-10-01), Patchornik et al.
patent: 3816254 (1974-06-01), Chibata et al.
patent: 4185090 (1980-01-01), McIntire
patent: 4328311 (1982-05-01), Rowley et al.
patent: 4695624 (1987-09-01), Marburg et al.
patent: 4830852 (1989-05-01), Marburg et al.
patent: 5204098 (1993-04-01), Szu et al.
patent: 5445817 (1995-08-01), Schneerson et al.
patent: 5565204 (1996-10-01), Kuo et al.
patent: 5651971 (1997-07-01), Lees
patent: 5693326 (1997-12-01), Lees
Landsteiner, The Specificity of Serological Reactions (Revised Ed.), Harv University Press, Cambridge, MA, 1945, only pp. 51 and 156-158 supplied.
Lees, A. et al., "Enhanced Immungencity of Protein-Dextran Conjugates: I. Rapid Stimulation of Enhanced Antibody Response to Poorly Immunogenic Molecules," Vaccine, vol. 12, No. 13, pp. 1160-1166, (1994).
Inman J.K., "Syntheses of Macromolecular Immunomodulators and Conjugates Employing Haloacetyl Reagents," Annals of the N.Y. Academy of Science, vol. 685, pp. 347-350, (1993).
Beuvery, E.C., et al., "Characteristics of Two Type of Meningococcal Group C Polysaccharide Conjugates Using Tetanus Toxiod as Carrier Protein," Develop. Biol. Standard, vol. 65, pp. 197-204, (1986).
Ibrahim et al., "Proportion of Protein A Bindable Molecules in Human IgM and IgA Antibodies to Seven Antigens," Mocrobial Pathogenesis, 15(3), 159-168 (Sep., 1993).
Lees et al., "Activation of Soluble Polysaccharides with 1-Cyano-4-dimethylaminopyridinum Tetrafluoroborate for Use in Protein-Polysaccharide Conjugate Vaccines and Immunological Reagents," Vaccine, 14(3), 190-198 (Feb., 1996).
Erlanger, "The Preparation of Antigenic Hapten-Carrier Conjugates: A Survey," Ch. 4 in Method in Enzmology, vol. 70, Part A, Vunakis and Langone (eds.), Academic Press, New York, NY, 1980, pp. 85-104.
Peters et al., "Chemical Cross-Linking: Reagents and Problems in Studies of Membrane Structure," Ann. Reviews in Biochemistry, 46, 523-551 (1977).
Crane L. Eric
Henry M. Jackson Foundation for the Advancement of Military Medi
LandOfFree
Coupling of unmodified proteins to haloacyl or dihaloacyl deriva does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Coupling of unmodified proteins to haloacyl or dihaloacyl deriva, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coupling of unmodified proteins to haloacyl or dihaloacyl deriva will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-542427